Advance your institution’s AMS goals by implementing penicillin allergy skin testing with PRE-PEN®

PRE-PEN® (benzylpenicilloyl polylysine injection USP) is the only FDA-approved skin test antigen reagent for the diagnosis of penicillin allergy.1,2

Check Mark Icon

Penicillin allergy skin testing may be a way to reduce use of broad-spectrum antibiotics and could have a significant and immediate impact on antibiotic usage3

Check Mark Icon

The National Quality Partners’ Antibiotic Stewardship Action Team recommends penicillin allergy skin testing as a component of a comprehensive antibiotic stewardship program4

Check Mark Icon

Penicillin allergy skin testing frequently allows for administration of less expensive agents that would have been avoided due to a reported allergy3,5

Performing penicillin allergy skin testing as soon as possible after admission allows clinicians more time to select the best antibiotic therapy and can reduce the time to first antibiotic dose.6

Negative results to penicillin allergy skin testing significantly reduced broad-spectrum antibiotic use7

negaitve thirty three percent icon P<.001

Vancomycin

negative sixty one percent P<.001

Clindamycin

negative thirty Six Percent P<.001

Fluoroquinolones

negative fifty percent P=.049

Carbapenems

negative sixty eight percent P=.009

Aztreonam

Testing supplies

Gather the testing supplies that you will need to perform one penicillin allergy skin test.

Reagents/Antigens
Single PRE-PEN ampule [0.2 cc]
Devices
(5) Skin testing devices
(1) Recording form
Reagents/Antigens
Penicillin G dilution (10,000 unites/mL) [0.2 cc]
Devices
(4) Syringe labels
(4) Syringes (detachable needles)
Reagents/Antigens
Histamine (1.0 mg/mL) [0.1 cc] Positive control
Devices
(4) Alcohol swabs
(7) Detachable needles total
Reagents/Antigens
Saline [0.2 cc] Negative control
Devices
(1) Reaction guide
Optional oral challenge: Although optional, the CDC recommends performing an oral challenge using an amoxicillin 250-mg capsule or another appropriate alternative
Reagents/Antigens Devices
Single PRE-PEN ampule
[0.2 cc]
(5) Skin testing devices (1) Recording form
Penicillin G dilution (10,000 unites/mL)
[0.2 cc]
(4) Syringe labels (4) Syringes (detachable needles)
Histamine (1.0 mg/mL) [0.1 cc]
Positive control
(4) Alcohol swabs (7) Detachable needles total
Saline [0.2 cc] Negative control (1) Reaction guide Optional oral challenge: Although optional, the CDC recommends performing an oral challenge using an amoxicillin 250-mg capsule or another appropriate alternative

Testing steps overview

Perform penicillin allergy skin testing with PRE-PEN® by following these 3 steps.

Expand All

STEP 1: Prick/Puncture testing

Apply a drop of each of the following, and then prick the skin using a skin-pricking device.

  • Histamine 1.0 mg/mL (positive control)
  • Saline (negative control)
  • PRE-PEN®
  • Diluted penicillin G (10,000 units/mL)

Wait 15-20 minutes to read, measure, and record.

Interpretation:

  • Histamine test site must measure at least 3 mm
  • Criterion for positive prick/puncture skin test: induration at least 3 mm greater than the negative control

IF PRICK/PUNCTURE TEST IS NEGATIVE...

STEP 2: Intradermal testing

Create blebs of 3 mm under skin:

  • Duplicate PRE-PEN®
  • Duplicate penicillin G (10,000 units/mL)
  • Single saline (negative control)

Mark perimeter of each bleb at placement.

Wait 15-20 minutes to read, measure, and record.

Interpretation:

  • Criteria for positive intradermal skin test:
    • Increase in size of original bleb of 3 mm or more
    • Itching and flare are commonly present
  • Criteria for negative intradermal skin test:
    • No increase in size of original bleb AND
    • No greater reaction than control site
  • Equivocal intradermal skin test:
    • Wheal only slightly larger than initial injection bleb and control site, with or without erythematous flare OR
    • Duplicates are contradictory

IF INTRADERMAL TESTING IN STEP 2 IS NEGATIVE...

STEP 3: Optional oral challenge

IF INTRADERMAL TESTING IN STEP 2 IS NEGATIVE...

Optional oral challenge: Although optional, the CDC recommends performing an oral challenge using an amoxicillin 250-mg capsule or another appropriate alternative.

Need
implementation
help? ALK can
support your testing efforts.

ALK is committed to providing you with the support and resources you need to successfully implement a penicillin allergy skin testing program. That’s why we have dedicated Implementation Specialists who can assist you with all aspects of testing, from creating customized testing protocols to providing administrative support and more.

Contact us at penallergytest@alk.net for assistance.

E-mail and Text Message Icon

Contact your Implementation Specialist to customize your penicillin allergy skin testing program and learn how testing can enhance antibiotic treatment.

CONTACT US
BACK TO TOP

References: 1. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration. Accessed October 3, 2021. 2. PRE-PEN. Prescribing information. ALK-Abelló, Inc.; 2013. 3. Heil EL, Bork JT, Schmalzle SA, et al. Implementation of an infectious disease fellow-managed penicillin allergy skin testing service. Open Forum Infect Dis. 2016;3(3):ofw155. doi:10.1093/ofid/ofw155 4. National Quality Forum. National Quality Partners Playbook: Antibiotic Stewardship in Acute Care. Published May 2016. Accessed July 13, 2021. www.qualityforum.org 5. King EA, Challa S, Curtin P, Bielory L. Penicillin skin testing in hospitalized patients with β-lactam allergies: effect on antibiotic selection and cost. Ann Allergy Asthma Immunol. 2016;117(1):67-71. doi:10.1016/j.anai.2016.04.021 6. Conway EL, Lin K, Sellick JA, et al. Impact of penicillin allergy on time to first dose of antimicrobial therapy and clinical outcomes. Clin Ther. 2017;39(11):2276-2283. doi:10.1016/j.clinthera.2017.09.012 7. Chen JR, Tarver SA, Alvarez KS, Tran T, Khan DA. A proactive approach to penicillin allergy testing in hospitalized patients. J Allergy Clin Immunol Pract. 2017;5(3):686-693. doi:10.1016/j.jaip.2016.09.045

INDICATION

PRE-PEN is indicated for the assessment of sensitization to penicillin (benzylpenicillin or penicillin G) in patients suspected to have clinical penicillin hypersensitivity. A negative skin test to PRE-PEN is associated with an incidence of immediate allergic reactions of less than 5% after the administration of therapeutic penicillin, whereas the incidence may be more than 50% in a history-positive patient with a positive skin test to PRE-PEN. These allergic reactions are predominantly dermatologic. Whether a negative skin test to PRE-PEN predicts a lower risk of anaphylaxis is not established. Similarly, when deciding the risk of proposed penicillin treatment, there are not enough data at present to permit relative weighing in individual cases of a history of clinical penicillin hypersensitivity as compared to positive skin tests to PRE-PEN and/or minor penicillin determinants.

IMPORTANT SAFETY INFORMATION

The risk of sensitization to repeated skin testing with PRE-PEN is not established. Rarely, a systemic allergic reaction including anaphylaxis (see below) may follow a skin test with PRE-PEN. To decrease the risk of a systemic allergic reaction, puncture skin testing should be performed first. Intradermal skin testing should be performed only if the puncture test is entirely negative.

PRE-PEN is contraindicated in those patients who have exhibited either a systemic or marked local reaction to its previous administration. Patients known to be extremely hypersensitive to penicillin should not be skin tested.

No reagent, test, or combination of tests will completely assure that a reaction to penicillin therapy will not occur. The value of the PRE-PEN skin test alone as a means of assessing the risk of administering therapeutic penicillin (when penicillin is the preferred drug of choice) in the following situations is not established:

  • Adult patients who give no history of clinical penicillin hypersensitivity.
  • Pediatric patients.

In addition, the clinical value of PRE-PEN where exposure to penicillin is suspected as a cause of a current drug reaction or in patients who are undergoing routine allergy evaluation is not known. Likewise, the clinical value of PRE-PEN skin tests alone in determining the risk of administering semisynthetic penicillins (phenoxymethylpenicillin, ampicillin, carbenicillin, dicloxacillin, methicillin, nafcillin, oxacillin, amoxicillin), cephalosporin-derived antibiotics, and penem antibiotics is not known.

In addition to the results of the PRE-PEN skin test, the decision to administer or not administer penicillin should take into account individual patient factors. Healthcare professionals should keep in mind the following:

  • A serious allergic reaction to therapeutic penicillin may occur in a patient with a negative skin test to PRE-PEN.
  • It is possible for a patient to have an anaphylactic reaction to therapeutic penicillin in the presence of a negative PRE-PEN skin test and a negative history of clinical penicillin hypersensitivity.
  • If penicillin is the drug of choice for a life-threatening infection, successful desensitization with therapeutic penicillin may be possible irrespective of a positive skin test and/or a positive history of clinical penicillin hypersensitivity.

Occasionally, patients may develop an intense local inflammatory response at the skin test site. Rarely, patients will develop a systemic allergic reaction, manifested by generalized erythema, pruritus, angioedema, urticaria, dyspnea, hypotension, and anaphylaxis. The usual methods of treating a skin test antigen-induced reaction—the applications of a venous occlusion tourniquet proximal to the skin test site and administration of epinephrine—are recommended. The patient should be kept under observation for several hours.

Pregnancy Category C: Animal reproduction studies have not been conducted with PRE-PEN. It is not known whether PRE-PEN can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. The hazards of skin testing in such patients should be weighed against the hazard of penicillin therapy without skin testing.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Please see full Prescribing Information for additional Important Safety Information.